Asthma

Agreement reached to codevelop Asmanex and Foradil combination product

Published in Biotech Business Week, May 5th, 2003

Novartis Pharma, AG, (NVS) and Schering-Plough Corp. have agreed to jointly develop and market worldwide a new combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Asmanex (mometasone furoate), an orally inhaled corticosteroid, will be combined with Foradil (formoterol fumarate), a selective, long-acting beta2-agonist, in a single inhalation device. Terms of the agreement are not being disclosed.

"Combining the therapeutic benefits of Asmanex and Foradil in a single device could significantly enhance the ability of doctors to control the symptoms of asthma and COPD," said Thomas Ebeling, CEO of Novartis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2003-05-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry